普通外文研报
Incyte Corporation: CMS Agreement Removes Opzelura Medicaid Overhang; Incremental Positive in Our View
研报英文原文证据摘录
Incyte Corporation: CMS Agreement Removes Opzelura Medicaid Overhang; Incremental Positive in Our View
Equity Research
U.S. Small & Mid Cap Biotechnology
22 June 2026
Incyte Corporation
CMS Agreement Removes Opzelura
Medicaid Overhang; Incremental
INCY OVERWEIGHTPositive in Our View
U.S. Small & Mid Cap POSITIVE
Favorable CMS agreement removes line extension risk for Biotechnology Price Target USD 117.00
Opzelura, driving a ~$246M one‑time benefit and supporting Price (18-Jun-26) USD 98.22
Potential Upside/Downside +19.1%structurally improved gross‑to‑net economics going forward. Source: Bloomberg, Barclays Research
Incyte disclosed via 8K this morning an agreement with CMS resolving litigation over
whether Opzelura should be treated as a “line extension” of Jakafi under Medicaid rebate Etzer Darout, PhD, MBA
rules. The agreement is favorable: Opzelura will be treated as a standalone product, +1 212 526 6940
resulting in a ~$246M one‑time 2Q26 benefit from accrual reversal and supporting a etzer.darout@barclays.com
structurally improved gross‑to‑net (GTN) profile going forward. We view this as BCI, US
incrementally positive, removing a regulatory overhang that could have weighed on the Gustave Diep, MD
long‑term economics of the Opzelura franchise. +1 212 526 0347
gustave.diep@barclays.com
What was at issue – Medicaid “line extension” designation risk BCI, US
The dispute centered on whether Opzelura would be treated as a line extension of Jakafi for
Lukas Shumway, PhD
Medicaid rebate purposes, which would have allowed CMS to apply Jakafi’s historical pricing +1 212 526 7293
baseline in calculating inflation rebates. This approach could have materially increased lukas.shumway@barclays.com
Opzelura’s rebate burden over time.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文，不做批量翻译；登录后在阅读器切换中文时才按需翻译。
打开研报阅读器